This includes the use asciminib as first in class inhibitor targeting the myristoyl pocket of BCR-ABL, combination treatments with established non-TKI drugs such as interferon and drugs with novel targets relevant to CML biology such as gliptins and thiazolidinediones. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.